Patients Refraining from Seeking Medical Care and Declining Sales of Prescription Pharmaceuticals Due to the Spread of COVID-19
First written in FY2021-Q1. 6 of 11 entries say "Mitigated", first in FY2022-Q1. Latest entry: FY2024.
The whole theme swung hardest in 2022: 3 of 10 companies on the "Worse" side.
4 other companies' latest entry also says "Mitigated".
- FY2024MitigatedAnnual report
「Sales increased as the number of patient visits recovered following the reclassification of COVID-19 as a Class 5 infectious disease, and the market expanded from the previous year.」
The recovery in patient visits and market expansion following the reclassification as a Class 5 infectious disease eased the impact of infection-related reductions in medical visits and pharmaceutical sales from the previous fiscal year. - FY2024-Q1MitigatedAnnual report
「Sales increased as the number of patient visits recovered following the reclassification of COVID-19 as a Class 5 infectious disease, and the market expanded from the previous year.」
For pharmaceuticals and other products, patient visits recovered following the reclassification of COVID-19 as a Class 5 infectious disease, and the market expanded year on year. The impact of reduced medical visits on sales eased from the previous fiscal year. - FY2023-Q3Market Edges Up Slightly as Related Product Sales Increase amid Renewed Spread of InfectionAnnual report
「The market for pharmaceuticals and other products expanded slightly year on year amid a renewed spread of COVID-19, as sales of products related to the infection increased despite continued reduced medical visits.」
While the renewed spread of the infection and reduced medical visits continued, the market for pharmaceuticals and other products expanded slightly year on year due to increased sales of infection-related products. - FY2023-Q2MitigatedAnnual report
「The market for pharmaceuticals and other products expanded despite pharmaceutical price reductions and the unprecedented spread of COVID-19, as reduced medical visits eased year on year and sales of COVID-19 treatments, anticancer drugs, and treatments for immune diseases increased, among other factors.」
Despite the large-scale spread of the infection and pharmaceutical price reductions, the market expanded as reduced medical visits eased year on year and sales of treatments, anticancer drugs, and treatments for immune diseases increased. - FY2022MitigatedAnnual report
「The market for pharmaceuticals and other products expanded year on year despite the impact of pharmaceutical price reductions and the COVID-19 pandemic, as reduced medical visits and other effects gradually recovered.」
As reduced medical visits recovered, the pharmaceutical market expanded year on year, and the impact eased somewhat from the difficult sales environment of the previous fiscal year. - FY2022-Q3MitigatedAnnual report
「The market for pharmaceuticals and other products expanded year on year as patient visits recovered against the backdrop of a high COVID-19 vaccination rate.」
The disclosure stated that, regarding reduced medical visits due to COVID-19, patient visits recovered against the backdrop of a high vaccination rate and the market expanded year on year. - FY2022-Q2Recovery and Deterioration Coexisted amid the Renewed Spread of VariantsAnnual report
「The market for pharmaceuticals and other products expanded year on year despite pharmaceutical price reductions and a renewed spread of infections due to COVID-19 variants, as reduced medical visits and other effects of COVID-19 gradually recovered.」
While the impact of the renewed spread of infections due to variants continued, reduced medical visits gradually recovered, and the pharmaceutical market expanded year on year, according to the disclosure. - FY2022-Q1MitigatedAnnual report
「Although the market for prescription pharmaceuticals and other products was affected by National Health Insurance drug price reductions, restrictions on visits to medical institutions due to COVID-19 gradually eased, and the market grew slightly compared with the same period of the previous year.」
The disclosure stated that reduced medical visits due to COVID-19 gradually recovered, and that the impact on the pharmaceutical market had eased somewhat from the severe conditions of the previous fiscal year. It did not state that the impact had been eliminated. - FY2021MaterialisedAnnual report
「Sales of pharmaceuticals and other products remained in difficult conditions due to the impact of the pharmaceutical price reduction implemented on 1 April 2020, as well as reduced medical visits and a decline in the number of surgeries resulting from the COVID-19 pandemic.」
The pharmaceutical price reduction, reduced medical visits, and decline in the number of surgeries had an actual impact on full-year pharmaceutical sales. - FY2021-Q2WorsenedAnnual report
「Sales of prescription pharmaceuticals and other products remained extremely difficult due to the impact of the National Health Insurance drug price reduction implemented on 1 April 2020, restrictions on visits to medical institutions amid concerns about a renewed spread of COVID-19, and a decline in the number of surgeries.」
In addition to reduced medical visits amid concerns about a renewed spread of COVID-19, the decline in the number of surgeries affected pharmaceutical sales, and the situation was described as very severe. - FY2021-Q1First statedAnnual report
「Sales of prescription pharmaceuticals and other products remained difficult due to the impact of the National Health Insurance drug price reduction implemented on 1 April 2020 and restrictions on visits to medical institutions caused by the spread of COVID-19.」
The disclosure stated that reduced visits to medical institutions accompanying the spread of COVID-19 had an actual impact on sales of pharmaceuticals and other products.